59 results about "Diabetes type ii" patented technology

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type II. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising Bifidobacterium bifidum W23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement.

The present invention relates to compounds of Formula (I):

wherein R¹, A, Y, n and m are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of orexin-1 receptor-related disorders and orexin-2 receptor-related disorders. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders.

The present invention provides a diabetes type II gene susceptivity and pre-warning detection kit, which is characterized in that seven nucleic acid (DNA and RNA) molecule markers are combined, wherein the seven nucleic acid (DNA and RNA) molecule markers comprise APM1 (+45), CDKAL1 (rs10946398), TCF7L2 (rs7903146) , CDKN2A/2B (rs10811661), KCNQ1 (rs2237892), VDR (FokI) and SLC30A8 (rs13266634). The kit comprises: specific amplification primer pairs and DNA sequencing primer pairs of the gene polymorphism loci, PCR reaction liquids, PCR product enzymolysis liquids and DNA sequencing reaction liquids. According to the present invention, detection is performed by using the kit, gene information is processed and analyzed, diabetes type II susceptivity of a healthy subject is evaluated, and guiding significance is provided for personalized treatment and health care of diabetes type II people.

The invention discloses a traditional Chinese medicine composition for treating diabetes type II and hyperlipoidemia. The traditional Chinese medicine composition is prepared from the following material medicines in portion by weight: 10 to 30 portions of astragalus root, 10 to 30 portions of gold theragran, 5 to 20 portions of coptis root, 10 to 20 portions of radix puerariae, 10 to 20 portions of tuckahoe, 6 to 20 portions of heterophylly falsestarwort root, 15 to 40 portions of yam, 10 to 20 portions of radix rehmanniae, 10 to 30 portions of rhizoma alismatis, 5 to 20 portions of dogwood, 10 to 30 portions of folium mori, and 5 to 20 portions of radix paeoniae rubra. The traditional Chinese medicine composition has the advantages that: all components are traditional Chinese medicines which are wide in source and relatively low in price; the traditional Chinese medicine composition can be prepared into tablets, soft capsules, hard capsules, oral liquid, pills or particles and conveniently taken; and the traditional Chinese medicine composition has simple preparation process, needs less equipment and is easy in operation.

The invention discloses a method for preparing alogliptin, a medicine for treating type II diabetes. The method comprises: 1) in the presence of copper acetate and triethylamine, 6-chloro-3-methyluracil and 2-cyano Benzyl bromide is carried out contact reaction in acetonitrile, and after reaction finishes, reaction solution is poured into water, filters, washes with water, dries to obtain 6-chloro-1-(2-isocyanobenzyl)-3-methylpyrimidine-2, 4-(1H,3H)-dione; 2) 6-chloro-1-(2-isocyanobenzyl)-3-methylpyrimidine-2,4-(1H,3H)-dione, (R )‑3‑tert-butyloxycarbonylaminopiperidine and potassium carbonate are mixed in DMF. After the reaction, add water, then extract with dichloromethane and concentrate to obtain (R)‑tert-butyl‑1‑(3‑ (2‑isocyanobenzyl)‑1‑methyl‑2,6‑dioxo‑1,2,3,6‑tetrahydropyrimidin‑4‑yl)piperidin‑3‑ylcarbamate; 3 ) dissolving the formate ester obtained in step 2) in ethanol and reacting with benzoic acid at 65-70°C, then cooling to -5-5°C for crystallization, filtering and drying to obtain alogliptin. The invention has simple steps, high yield and faster reaction.

Short peptides and derivatives or analogs thereof for the treatment or prevention of IAAP related disorders, in particular amyloid deposits associated with Type I or Type II diabetes are herein described. These peptides and/or their derivatives have been designed to inhibit the formation of amylin fibrils which are implicated in the pathogenesis of diabetes Type II as well as to dissolve the fibrillar deposits already formed

The invention relates to a pharmaceutical composition for treating diabetes type II. The pharmaceutical composition contains an effective dose of compound and a pharmaceutically acceptable carrier, wherein the structure of the compound is as shown in the specification. The compound provided by the invention has an obvious effect on diabetes type II and can be developed into a new pharmaceutical composition which is effective clinically.

The technical problem to be solved by the present invention is to prolong the half-life of an Exendin-4 polypeptide and to improve the stability and the safety of the existing Exendin-4 polypeptide-containing fusion protein. The scheme for solving the technical problem is to provide a new fusion protein containing the Exendin-4 polypeptide, wherein the structure of the fusion protein sequentially comprises Exendin-4, a connecting peptide, Exendin-4, a connecting peptide and an IgG4Fc mutant from the nitrogen terminal. According to the present invention, the provided fusion protein containing the Exendin-4 has characteristics of good stability, long half-life and low toxic-side effect; and the fusion protein of the invention can be used for treatment of diabetes type I and diabetes type II, and has high clinical application value.

Provided herein are methods of inhibiting agouti or agouti-related protein (AGRP) in a cell or in an individual in need thereof, comprising administering to the cell or the individual an effective amount of an agent that induces corin expression, activity or a combination thereof in the cell or individual. The invention also provides a method of treating obesity in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual. Further provided is a method of treating diabetes type II in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual.

The invention discloses a crystal form of dapagliflozin and preparation method thereof. The dapagliflozin is stirred and dissolved with 1,2-propylene glycol in an organic solvent; then a low-polar solvent is added, and cooling crystallization is carried out at certain temperature; the mixture then is filtered to obtain a solid; the solid is subjected to pressure-reduced vacuum drying to prepare acrystal form compound of dapagliflozin, which has high purity and has obvious structural features of the crystal. The crystal form compound of dapagliflozin has good thermal stability and allows large-scale production. The crystal form compound and a composition thereof are mainly used for treatment on diabetes type II.